top of page

Detect cancers earlier, affordably & accurately

Monitor multiple cancers in healthy people with one blood test using PCR

Save lives with early cancer detection

Cancer is the second leading cause of death now and is estimated to be the No.1 cause of death globally by the mid-2020s. Multi-cancer early detection could lead to a 40% reduction in cancer deaths.

Screen 12+ cancers in one test

miRoncol can detect 12+ types of solid tumor cancers accountable for ~60% of total cancer death today.

High Accuracy

miRoncol test can detect early stage cancers with high detection rate while keep false positive rate low.

Non-invasive and convenient

miRoncol test is based on a simple blood draw and can be done at annual check up.

Low cost and easy to scale up

miRoncol brings an affordable solution that can be done through PCR which is mature and cheaper. It can also expand and roll out worldwide more quickly.

miRNA based technology

Discovery of microRNA(miRNA) won the 2024 Nobel Prize in Medicine

Promising biomarkers for disease diagnosis and prognosis

Basic Properties
  • Discovered in 1993

  • Short single-stranded

  • Stable and detectable in blood

Functions
  • Non-coding

  • Regulate gene expression

  • Different expression profile in cancer patients

Scientific rigor

Publications

Publications

Peer-reviewed publications
Scientific Reports Logo_White.png

Noninvasive multi-cancer detection using blood-based cell-free microRNAs

Cancer_white.png

A Novel Blood-Based microRNA Diagnostic Model with High Accuracy for Multi-Cancer Early Detection

Presentations

Poster presentation at the 2024 Early Detection of Cancer Conference

Poster presentation at 2022 Annual Meeting of American Society of Clinical Oncology.​

Poster presentation at the 2024 ASCO Breakthrough and won the abstract award.​

Poster presentation at the 2022 Annual Meeting of American Association for Cancer Research.

Poster presentation at 2023 European Society for Medical Oncology Congress Meeting​

At the 2021 World Conference on Lung Cancer, our study was not only selected for oral presentation, but also highlighted in the Meeting News.​​

REMOVE
Barriers to cancer screening
REDUCE

Missed opportunities for early detection
REASSURE
Peace of mind

>30% of Americans will be diagnosed with cancer in their lifetime.

​

>15% of Americans will die from cancer in their lifetime.

​

Cancer is the #1 leading cause of death for Americans younger than 65 years old.

​

Early detection of cancers can save lives by increasing the survival rate by 7-12 times.

​

Cancer touches all of us.

 

You can help make a change.

miRoncol 400dpiLogoCroppedNewColor
miRoncol
A miracle in oncology made possible with miRNA

601 Walnut St., #715

Philadelphia, PA 19106, USA

​

1000 Innovation Dr., 5F

Ottawa, ON K2K 3E7, Canada

​

DISCLAIMER

This website may contain certain statements, estimations, projections, assessments and other information with respect to the anticipated future performance of the Company and/or its market and involve risks and uncertainties. Actual results or future business decisions of the Company may differ materially from any expectations, projections or predictions made or implicated in statements made in this website. While the Company believes that the information contained herein is accurate, it expressly disclaims any and all liability for representations or warranties, expressed or implied, contained in, or for omissions from, this website or any other communication transmitted or made available herein. Any prospective website user acknowledges his/her responsibility to perform a due diligence review prior to consummating a transaction with the Company. Included in this website are certain declarations by the Company with respect to its anticipated future performance. These declarations are based on estimates and assumptions by the Company that are subject to economic and competitive uncertainties beyond the control of the Company. The Company does not provide representation or warranty with regard to the declarations and there can be no assurance that the future results will be realized or that actual results will not be significantly different from those projected. The Company is not obligated to update or revise any future declarations. The Company and its respective affiliates, directors, officers, employees, consultants and representatives expressly disclaim any and all liability relating to or resulting from the utilization of any information contented in this website. The Company does not have any obligation to provide with access to additional information.

© 2021 by miRoncol. All rights reserved.

bottom of page